Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J, Doerr J, Jarosch S, Lam D, Klein H, Pekcec A, Chehimi SN and 4 more

Show all authors

Crist RC, Reiner BC, Hayes MR, Augustin R

Molecular metabolism2 Feb 2026

PMID41638399PMCIDPMC12925197DOI10.1016/j.molmet.2026.102326PepBankPUB-41638399

Download PDF PubMedAsk about this study

Jump to 4 results

Summary

Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH). Preclinically, survodutide demonstrated body weight lowering efficacy through decreased energy intake and increased energy expenditure. Here, we investigated the central site of action of survodutide and provide further insights into its mechanism of action in reducing body weight. We assessed GCGR and GLP1R expression in human and mouse circumventricular organs (CVOS) and showed for the first time that GCGR is barely detectable in area postrema (AP) and arcuate nucleus of the hypothalamus (ARH) at the single cell level. In contrast, GLP1R is expressed in these tissues. Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei, without evidence of uniformly crossing the blood-brain-barrier. In addition, c-Fos labeling showed that multiple nuclei associated with the control of food intake were activated by survodutide. Consistent with the hypothesis that the intake suppressive effects of survodutide are GLP-1R dependent, a long-acting GCGR agonist did not induce neuronal activation in satiety-mediating regions, nor reduced food intake but showed reduction in body weight. These data further support the dual mode of action of survodutide and its potential to provide clinical benefit for people with obesity and/or MASH.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In mice, fluorophore-labelled survodutide directly accessed the circumventricular organs and adjacent hypothalamic and hindbrain nuclei, without evidence of uniformly crossing the blood-brain barrier.
In plain wordsIn mice, survodutide reached brain regions near the blood-brain barrier that control appetite, but did not clearly enter the whole brain.
Peptide
Survodutide
Outcome
Not applicableBrain distribution of fluorophore-labelled survodutide
Study
mousen: not reported in source
mouse brain
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei, without evidence of uniformly crossing the blood-brain-barrier.
Show in the study text Report a problemFND-4163839903
02AnimalAnimal study (in vivo)Mechanism
In mice, c-Fos labeling showed that survodutide activated multiple nuclei associated with the control of food intake.
In plain wordsIn mice, survodutide activated several brain regions that help control food intake.
Peptide
Survodutide
Outcome
Increasec-Fos neuronal activation in food-intake nuclei
Study
mousen: not reported in source
mouse brain
Outcome group
Appetite and food intake · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
In addition, c-Fos labeling showed that multiple nuclei associated with the control of food intake were activated by survodutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei, without evidence of uniformly crossing the blood-brain-barrier.
Show in the study text Report a problemFND-4163839904

Studies that did not test the peptide alone2

In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Survodutide.

03LabNot a test of Survodutide aloneEx vivo tissueMechanism
In human and mouse circumventricular organs, GCGR was barely detectable in the area postrema and arcuate nucleus of the hypothalamus at the single cell level.
In plain wordsIn human and mouse brain tissue, the glucagon receptor was barely detectable in two brain regions that control appetite.
Peptide
Survodutide
Outcome
Not applicableGCGR expression in area postrema and arcuate nucleus
Study
human and mousen: not reported in source
circumventricular organ tissue (area postrema, arcuate nucleus)
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
We assessed GCGR and GLP1R expression in human and mouse circumventricular organs (CVOS) and showed for the first time that GCGR is barely detectable in area postrema (AP) and arcuate nucleus of the hypothalamus (ARH) at the single cell level.
In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Survodutide.
Show in the study text Report a problemFND-4163839901
04LabNot a test of Survodutide aloneEx vivo tissueMechanism
In human and mouse circumventricular organs, GLP1R was expressed in the area postrema and arcuate nucleus of the hypothalamus.
In plain wordsIn human and mouse brain tissue, the GLP-1 receptor was present in two brain regions that control appetite.
Peptide
Survodutide
Outcome
Not applicableGLP1R expression in area postrema and arcuate nucleus
Study
human and mousen: not reported in source
circumventricular organ tissue (area postrema, arcuate nucleus)
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
In contrast, GLP1R is expressed in these tissues.
1 context sentence(design, population, supporting numbers)
Summary · context
We assessed GCGR and GLP1R expression in human and mouse circumventricular organs (CVOS)
In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Survodutide.
Show in the study text Report a problemFND-4163839902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.